Published in Clin Transl Oncol on December 19, 2016
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med (2010) 10.21
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol (2009) 4.53
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol (2015) 4.00
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol (2002) 3.25
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer (1987) 3.24
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr (2006) 2.89
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg (2006) 2.70
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology (2005) 2.60
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer (2011) 2.59
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol (2013) 2.58
Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park) (2014) 2.48
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol (2014) 2.47
Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.35
Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg (1999) 2.23
Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc (2009) 2.23
Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery (2014) 2.22
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol (2004) 2.12
Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. Ann Surg (2014) 2.09
Preoperative biliary drainage of severely jaundiced patients increases morbidity of pancreaticoduodenectomy: results of a case-control study. World J Surg (2014) 2.06
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology (2002) 2.04
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer (2012) 2.01
Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol (2007) 1.96
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2014) 1.85
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer (2013) 1.85
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer (2012) 1.80
Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.79
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut (2015) 1.59
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) 1.54
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol (2005) 1.44
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol (2010) 1.38
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol (2013) 1.36
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist (2014) 1.34
Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis (2001) 1.34
Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol (2011) 1.33
Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery (2011) 1.32
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP (2012) 1.32
Diagnosis of pancreatic cancer. HPB (Oxford) (2006) 1.29
A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg (2011) 1.29
Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol (2011) 1.28
Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol (2010) 1.24
Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am (2012) 1.23
Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology (2014) 1.22
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas (2013) 1.21
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol (1999) 1.15
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer (2011) 1.12
Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg (2006) 1.11
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol (2014) 1.11
Carcinoma of the periampullary region: who benefits from portal vein resection? Am J Surg (1996) 1.05
Laparoscopic pancreaticoduodenectomy: a systematic literature review. Surg Endosc (2014) 1.05
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol (2015) 1.03
A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. Am J Surg (1988) 1.00
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Am J Clin Oncol (2017) 0.99
Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology (2014) 0.98
A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage (2013) 0.98
Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg (2011) 0.96
When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. Surgery (2014) 0.94
Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP (2013) 0.93
Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. Ann Surg (2015) 0.92
Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas (2011) 0.91
Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol (1999) 0.90
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract (2015) 0.89
Robotic surgery of the pancreas: The current state of the art. J Surg Oncol (2015) 0.88
Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist (2013) 0.87
Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol (2011) 0.87
Laparoscopic gastro- and hepaticojejunostomy for palliation of pancreatic cancer: a case controlled study. Surg Endosc (1999) 0.86
Clinical and pathologic features of familial pancreatic cancer. Cancer (2014) 0.86
Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology (2014) 0.86
Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery (2012) 0.85
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis. Rev Recent Clin Trials (2015) 0.84
Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol (2013) 0.83
Ca19-9 and pancreatic cancer: Is it really that good? J Gastrointest Oncol (2012) 0.83
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) (2013) 0.82
Pain syndromes and pharmacologic management of pancreatic cancer pain. J Pain Symptom Manage (1988) 0.82
PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer (2015) 0.81
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol (2015) 0.76
SEOM Clinical Guideline of localized rectal cancer (2016). Clin Transl Oncol (2016) 0.75
Surgery for pancreatic ductal adenocarcinoma. Clin Transl Oncol (2017) 0.75